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The laboratory rabbit (Oryctolagus cuniculus) is widely used as a model for a variety of inherited and 
acquired human diseases. In addition, the rabbit is the smallest livestock animal that is used to 
transgenically produce pharmaceutical proteins in its milk. Here we describe a protocol for high-
efficiency germline transgenesis and sustained transgene expression in rabbits by using the Sleeping 
Beauty transposon system. The protocol is based on co-injection into the pronuclei of fertilized 
oocytes of synthetic mRNA encoding the SB100X hyperactive transposase, together with plasmid 
DNA carrying a transgene construct flanked by binding sites for the transposase. The translation of the 
transposase mRNA is followed by enzyme-mediated excision of the transgene cassette from the 
plasmids and its permanent genomic insertion to produce stable transgenic animals. Generation of a 
germline-transgenic founder animal by using this protocol takes approximately two months. 
Transposon-mediated transgenesis compares favorably in terms of both efficiency and reliable 
transgene expression to classic pronuclear microinjection, and offers comparable efficacies (numbers 
of transgenic founders obtained per injected embryo) to lentiviral approaches, without limitations on 
vector design, issues of transgene silencing as well as the toxicity and biosafety concerns of working 
with viral vectors. 
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INTRODUCTION 
The laboratory rabbit is the third most used experimental mammal (behind mice and rats) in the EU 
(http://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=COM:2010:0511:REV1:EN:PDF), being a 
prolific animal with a short generation time, that can be raised in specific pathogen-free conditions. 
The rabbit is the primary source of polyclonal antibodies, and recent transgenic rabbit models are 
capable of a significantly increased level of antibody production1,2. Transgenic rabbits are also used as 
bioreactors for the production of pharmaceutical proteins. Ruconest®, the second milk-born 
recombinant product worldwide, produced and purified from transgenic rabbit’s milk, has already 
reached the EU market (http://www.pharming.nl/index.php?act=prod). 
Rodents, rabbits and other mammals all have particular limitations and strengths as animal 
models in biomedical research and are best regarded as complementary to each other. One example 
is Alzheimer disease, where animal models from additional species are expected to compensate for 
the limitations of mouse models and provide more reliable evaluation of novel diagnostic and 
therapeutic strategies3. Among the already existing transgenic rabbit strains, the models of 
cardiovascular diseases are the most important. The spontaneous mutant Watanabe heritable 
hyperlipidemic rabbit was pioneering as animal model of lipid metabolism and atherosclerosis4, and 
was followed by more than twenty different transgenic rabbit models, which altogether contributed to 
the development of both hypolipidemic and/or anti-atherosclerotic compounds5. The limitations of 
transgenic mouse models, which have failed to completely mimic the human phenotype of inherited 
long QT syndrome, an inborn arrhythmogenic heart disease, made necessary to create transgenic 
rabbit models6. Due to their large eyes, rabbits, along with other mid-sized and large animal models, 
are important in testing new treatments for and surgical methods in eye diseases7. Transgenic rabbits 
carrying a rhodopsin mutation showed rod-dominant progressive retinal degeneration8 and serve as 
pathophysiology models of new therapeutic treatments9. 
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Germline transgenesis in rabbits 
Since the first transgenic rabbits were created by pronuclear microinjection10, this has been the 
method of choice in the majority of about 200 publications on transgenic rabbits. The efficiency of this 
method has not changed much: on average about 1-5% of the pups born from embryo transfer are 
transgenic. In addition to this low transgenesis rate, the integration site and copy number of a plasmid-
based transgene is uncontrolled, therefore unwanted ectopic expression or transgene silencing might 
occur. Transgenesis by artificial chromosomes (YAC, BAC) ensures improved expression patterns, 
because those large-size vectors include most if not all the regulatory regions and the expression 
domains of the gene of interest (GOI)2,11. However, microinjection of transgenes cloned into artificial 
chromosomes is technically demanding due to their large size and fragility, and the integrity of the 
chromosomally integrated transgene should be strictly controlled. 
Lentiviral transgenesis was reported to be a promising and efficient novel tool in different non-
rodent species, where the ineffective and expensive pronuclear microinjection was the only available 
method (for review see ref. 12). Somewhat contrary to expectations, the first data on lentiviral 
transgenesis in rabbit revealed that, although the SIV-based lentiviral transduction resulted in high 
numbers of transgenic founders, the germline transmission rate was very low due largely to mosaic 
transgene expression in the founder animals, making this method unsuitable for upscaling in this 
species13. 
Contrary to mouse, swine and ruminants, the efficiency of somatic cell nuclear transfer (SCNT) 
in rabbits using standard methods is very low, regardless of the type of nuclear donor cells, and only a 
negligible percentage of offspring remain healthy and reach sexual maturity (puberty)14-17. Therefore, 
this method has limited practical use in rabbit transgenesis. 
 
Transgenesis with the Sleeping Beauty transposon 
Similarly to retroviruses, DNA transposons integrate into the chromosomes of the host cells, a feature 
that forms the basis of their use as gene vectors. In nature, these elements contain a gene encoding a 
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transposase enzyme flanked by inverted terminal repeats (ITRs) that carry binding sites for the 
transposase. Under laboratory conditions, transposons are applied as bi-component vector systems, 
in which a DNA sequence of interest can be cloned between the transposon ITRs and mobilized by 
supplementing the transposase enzyme in trans as an expression plasmid or as in vitro synthesized 
mRNA (Fig. 1A). During transposition, the transposase excises the transposon carrying the GOI from 
its donor plasmid, and integrates it into a chromosomal locus (Fig. 1B). Based on fossil record of 
transposons that were active >10 million years ago in fish genomes, an ancient transposon was 
“awakened” (molecularly reconstructed), and named Sleeping Beauty (SB) after the Grimm brothers’ 
fairy tale18. SB was the first transposon ever shown to be capable of efficient transposition in 
vertebrate cells, thereby enabling new avenues for genetic engineering in animal model species 
(reviewed in ref. 19). In addition to SB, the piggyBac and Tol2 transposons have also been developed 
as gene transfer tools for vertebrate genetics19. 
SB transposon-based gene delivery combines the advantages of retroviral vectors (permanent 
gene insertion into recipient genomes) with those of naked DNA molecules (simple, safe and 
inexpensive). Because transposition is a cut-and-paste mechanism that only involves DNA, 
transposon vectors can tolerate larger and more complex transgenes. The SB system is not strictly 
limited by the size of expression cassettes20. Indeed, inserts as large as BAC were recently shown to 
transpose with SB at reasonable efficiencies in mouse ESCs21. The desirable outcome when 
performing transgenesis is the integration of a single copy transgene into a genomic locus that is not 
disturbing endogenous gene functions. The insertional spectrum of the SB transposon satisfies this 
criterion well, because it integrates at TA dinucleotides nearly randomly, resulting in ~60 % of the SB 
transposon integrations being intergenic22-25. SB transposon vectors have been shown to efficiently 
deliver a wide variety of transgene cassettes (reviewed in refs. 19, 26 and 27), including shRNA 
expression cassettes to obtain stable RNAi knockdown cell lines28 as well as cassettes inducing gain-
of-function and loss-of-function gene mutations19,26,27. Importantly, the basic components of the 
transposon systems (i.e., the transposon ITRs and the transposase) are universally applicable for 
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gene transfer; it is the cargo DNA cloned between the ITRs that is tailored to the intended use, i.e. 
mutagenesis, germline transgenesis or somatic gene therapy. 
Because the transposase is only transiently present in the cell, the integrated transposon is 
stable (will not undergo further rounds of transposition). This feature makes transposons easily 
controllable DNA delivery vectors that can be used for versatile applications, including germline gene 
transfer. A hyperactive variant of the SB transposase, called SB100X, was recently developed by in 
vitro evolution29, and shown to support efficient germline transgenesis in mice29-31, rats30,31, rabbits30 
and pigs32,33. The SB100X-mediated protocol was optimized by carefully titrating the relative amounts 
of transposase and transposon to obtain optimal rates of transgenesis to generate founders, and was 
extensively evaluated for efficacy, toxicity, mosaicism, germline transmission, insertion site 
preferences, transgene copy number and silencing. Genotyping of numerous transgenic lines 
produced by SB-transposition demonstrated single-copy integrations of the transposon as expected 
from the cut-and-paste integration reaction catalyzed by the SB-transposase30. The numbers of 
integrations per genome was shown to be dependent on and hence controllable by the concentration 
of both components of the transposon system in the injection cocktail30. One of the most important 
aspects of using this transposon-mediated transgenic protocol is that no major mosaicism was 
observed, and transgene expression was maintained for several generations in all species tested. The 
high germline transmission rate using this protocol is in sharp contrast to any current non-viral or viral 
approach to transgenesis. This is likely due to the very nature of transgene integration: transposition 
results in precise (the ends of the integrating DNA are well defined) genomic integration of monomeric 
transgene units within a short timeframe following administration, thereby minimizing mosaicism. 
Furthermore, unlike retroviral vectors34-37, SB100X transposase-catalyzed transgene integration does 
not seem to trigger transcriptional silencing24,30. Therefore, the application of the Sleeping Beauty 
transposon system described here can significantly enhance the rabbit genomic toolbox. 
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Limitations 
DNA transposons, including SB, piggyBac and Tol2, are regulated by overproduction inhibition, which 
means that overexpression of the transposase has a negative effect on the efficiency of 
transposition24,38. The practical consequence of this phenomenon is that an optimal ratio of transposon 
donor plasmid and transposase mRNA needs to be established. As a rule of the thumb, the injection 
mixture should contain 5 ng/μl SB100X mRNA and 0.4 ng/μl transposon donor plasmid for a SB vector 
of the total size of ~6.1 kb (containing a ~2.5 kb transgene cassette)29. For larger transgenes, the 
concentration of the donor plasmid in the microinjection mixture has to be increased to maintain 
optimal molar ratios between transposon and transposase. It has been found that embryos tolerate 
concentrations of transposon donor plasmid up to 2 ng/μl in mice29. 
 
Experimental Design 
The generation of transgenic rabbits by SB-mediated transgenesis is achieved through microinjection 
of a plasmid carrying a GOI cloned between the ITRs of SB, and synthetic transposase mRNA (Fig. 1) 
into the pronucleus of a zygote, with frequencies of transgenic founders (per born live pup) of 15 % or 
higher30. The protocol consists of the following major stages: 
Preparation of Sleeping Beauty transposon components for microinjection (Steps 1-26). This 
includes molecular cloning of a GOI into SB transposon vectors; preparation of mRNA encoding the 
transposase by in vitro transcription; and preparation of a nucleic acid mixture consisting of the 
purified transposon plasmid and the transposase mRNA. Synthetic mRNA encoding the SB100X 
transposase can be produced from either the pCMV(CAT)T7-SB100X or the pcGlobin2-SB100X 
plasmids29 (see Reagents). The latter vector supports in vitro synthesis of SB100X mRNA containing 
zebrafish β-globin 5’- and 3’-UTRs and a 30-mer synthetic poly(A) sequence, from a T7 promoter39.  
Transgenesis with Sleeping Beauty in rabbits (Steps 27-49). This includes preparation of donor 
animals, superovulation of donors, collection of zygotes, microinjection of the nucleic acid mixture into 
zygotes and transfer of the microinjected embryos into surrogate mothers. The exact timing of 
superovulation and embryo collection is critical, and needs to be optimized to obtain sufficient numbers of 
 8 
freshly fertilized, one cell-stage oocytes with clearly visible pronuclei. Contrary to mouse, rat and swine, 
the early development of rabbit embryos is rapid, therefore it could easily happen that some of the 
embryos will be in the two-cell stage by the time the embryo collection is finished. For the same reason it is 
not suggested to significantly increase the number of donor does per experimental day. 
Genotyping of transgenic animals (Steps 50-76). This includes PCR-based analysis of F0 as well 
as F1 offspring to establish founders and germline transmission. A simple, quick PCR test can be 
applied to determine the presence of integrated transposon sequences from genomic DNA samples. 
The PCR primers amplify sequences in the left ITR of SB; thus, this protocol can be universally 
applied irrespective of the GOI that was cloned into the SB vector. In order to assess copy numbers of 
integrated transposons and map the genomic integration sites, a ligation-mediated PCR procedure is 
applied40. The procedure consists of a restriction enzyme digest of the genomic DNA, ligation of an 
oligonucleotide adapter to the ends of the fragmented DNA, PCR amplification of a transgene/genomic 
DNA junction in two rounds of nested PCR with primers specific to the adapter and to the ITRs of the 
SB transposon, and sequencing of the junctions to map the insertion to the reference genome41. 
Finally, a locus-specific PCR is applied to distinguish and track the individual integrations in the F1 
and later generations. 
 
MATERIALS 
Reagents 
Animals 
10 donor and 10 recipient rabbits are sufficient to produce at least two independent transgenic founders in 
a well-managed animal unit with trained personnel. The most frequently used breed for transgenesis is the 
New Zealand White (Harlan Laboratories, Indianapolis), but depending on the aim of the experiment, it 
could be replaced with Hycole (Sarl Hycole, Marcoing, France) or ZIKA® hybrid rabbits (Dr. Zimmermann 
GbR, Schweizerhof, Germany). In some countries local breeds are also successfully used e.g. Japanese 
White rabbits in Japan and China (KBT Oriental Corporation, Saga, Japan). Laboratory rabbits can also be 
 9 
obtained from the distributors of Charles River (Charles River Laboratories International Inc., USA) or from 
authorized local breeders. The rabbit does should be sexually mature and at an age of 16-20 weeks, 
weighing 3.0-3.5 kg on average. The rabbit bucks should be at least 18-20 weeks old to provide good 
quality semen. 
! Caution Experiments involving rabbits must conform to national and institutional regulations. Animal 
handling requires special license(s). 
 
Molecular biology reagents 
• mMessage mMachine® T7 kit (Invitrogen/Ambion, cat no. AM1344) 
• Plasmid DNA preparation kit (Qiagen, cat no. 27106) 
• QIAquick Gel Extraction Kit (Qiagen, cat no. 28704) 
• Agarose (DNase, RNase none detected) (Sigma–Aldrich, cat no. A4718) 
• Ethidium bromide (Sigma–Aldrich, cat no. E1015-10ml) ! Caution This is a hazardous chemical. 
Avoid contact with skin, eyes and airways. 
• ClaI restriction endonuclease (New England Biolabs, cat no. R0179S) 
• BfaI restriction endonuclease (New England Biolabs, cat no. R0568S) 
• DpnII restriction endonuclease (New England Biolabs, cat no. R0543S) 
• Taq DNA polymerase, provided with PCR buffer (10X) and MgCl2 (25 mM) (New England Biolabs, 
cat no. M0267S) 
• Oligonucleotides (Integrated DNA Technologies, Inc.) 
• dNTP (10 mM) (New England Biolabs, cat no. N0447S) 
• Sodium chloride (Sigma–Aldrich, cat no. S3014)  
• Sodium acetate 3 M pH 5.5 (RNase-free) (Invitrogen/Ambion, cat no. AM9740) 
• RNaseZap (Invitrogen/Ambion, cat no. AM9780) 
• 2-propanol (ROTH, cat no. 6752.1) 
• Ethanol (RNase-free) (MERCK, cat no. 108543) 
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• Water (RNase-free, filtered) (Sigma–Aldrich, cat no. W4502) CRITICAL The use of filtered RNase-
free water is recommended in solutions coming in contact with the injection material. 
• Phenol/chloroform/isoamyl alcohol, Roti®-Phenol/C/I (ROTH, cat no. A156.2) ! Caution This is a 
hazardous chemical. Avoid contact with skin, eyes and airways. 
• Chloroform/isoamyl alcohol, Roti®-C/I (ROTH, cat no. X984.2) ! Caution This is a hazardous 
chemical. Avoid contact with skin, eyes and airways. 
• DEPC (Sigma–Aldrich, cat no. D5758) ! Caution This is a hazardous chemical. Avoid contact with 
skin, eyes and airways. 
• 5x TBE buffer, Nuclease-free (Sigma–Aldrich, cat no. 93306) 
• TE buffer (Sigma–Aldrich, cat no. 93283) 
• T4 DNA ligase, provided with ligase buffer (10X) (New England Biolabs, cat no. M0202S) 
• 100-bp DNA Ladder (Thermo Scientific, cat no. SM0242) 
• 100-10.000-bp DNA Ladder (Thermo Scientific, cat no. SM0331) 
• pGEM-T Vector Systems (Promega, cat no. A3600) 
• Transposon donor plasmid: pT2/BH (http://www.addgene.org/26556/) or pT2/HB 
(http://www.addgene.org/26557/) are available from Addgene. 
• Transposase expression plasmids: pCMV(CAT)T7-SB100X (http://www.addgene.org/34879/) is 
available from Addgene, and pcGlobin2-SB100X is available from Dr. Zsuzsanna Izsvak, Max 
Delbrück Centrum for Molecular Medicine, Berlin. 
Animal work 
• Injection buffer, EmbryoMax® (Millipore, cat no. MR-095-10 F) 
• PBS, pH 7.4: (Sigma–Aldrich, cat no. P4417) 
• Millipore Express PLUS membrane 0.22 µm (Merck Millipore, cat no. GPWP01300) 
• Repel-Silane (Sigma–Aldrich, cat no. Z719951-1CS) 
• Heat-inactivated FCS (Gibco, cat no. 10500-064) 
• Mineral oil/Embryo tested (Sigma–Aldrich, cat no. M8410) 
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• Penicillin/streptomycin (100×) (Gibco, cat no. 15140-122) 
• Medasept coloured skin desinfectant (Molar chemicals, cat no. 41730-000-310) 
• 10 % ketamine (CP-Ketamin, Cp-Pharma Handelsges mbH) 
• 2 % xylazine (CP-Xilazin, Cp-Pharma Handelsges mbH) 
• Pregnant mare's serum gonadotropin (PMSG) (Sigma–Aldrich, cat no. G4877) 
• Human chorionic gonadotropin (hCG) (Sigma–Aldrich, cat no. C1063) 
• Gonadotropin releasing hormone (GnRH) (Sigma–Aldrich, cat no. L8008) 
• Follicle stimulating hormone (pFSH) (Sigma–Aldrich, cat no. F2293) 
• Oxytocin (Sigma–Aldrich, cat no. O3251) 
• Betadine solution (Fisher Scientific, cat no. NC9238358) 
• Shotapen INJ broad-spectrum antibiotics (Virbac Animal Health) 
 
EQUIPMENT 
For molecular biology 
• Refrigerated centrifuge capable of high speed (12000 × g) (Thermo Scientific, cat no. 75008162) 
• Water bath, 37°C (Thermo Scientific, cat no. 2824) 
• NanoDrop® ND-2000 Spectrophotometer (Thermo Scientific, cat no. 91-ND-2000) 
• Milli-Q Water Purification System (Merck Millipore, cat no. ZRXQ003T0) 
• 1.5-ml tubes, free of DNase and RNase (Eppendorf, cat no. 0030123.328) 
• Pipette tips, free of DNase and RNase (Eppendorf, cat no. 0030077.504 (0.1– 10 µl), cat no. 
0030077.539 (2–20 µl), cat no. 0030077.555 (2–200 µl), cat no. 0030077.571 (50–1000 µl)) 
• Thermal cycler capable of temperature increments for touchdown PCR (Thermo Scientific, cat no. 
TCA0001) 
• Electrophoresis apparatus including running chamber, well combs, gel tray and power supply 
(BioRad, cat no. 164-5050) 
• 100-ml glass flasks (SIMAX, cat no. B1812) 
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For animal work 
• Microcapillaries (Harvard Apparatus, GC100-T15 cat no. 30-0036 and GC100-TF15 cat no. 30-0039, 
Brand cat no. 701902) ! Caution These are sharp objects; dispose in an institution-approved container. 
• Engraving pen (Sigma–Aldrich, cat no. Z225568-1EA) 
• Bunsen burner (Sigma–Aldrich, cat no. Z270318-1EA) 
• Mouthpiece, 15-inch aspirator tube and microcapillary holder (Sigma–Aldrich, cat no. P0799) 
• Transfer capillary setup (home-made, 1 ml syringe with/brand capillary) ! Caution These are sharp 
objects; dispose in an institution-approved container. 
• Suture wound clips (Metal suture clips for mice, 7 mm) (Leica, cat no. 39465204) 
• Introcan Safety IV indwelling cannula (BBraun, cat no. 4254171B) ! Caution These are sharp objects; 
dispose in an institution-approved container. 
• 18-gauge mixing needle (Terumo Medical Corporation, cat no. BN-1838) 
• 20-ml syringe (Terumo Medical Corporation, cat no. SS+20L1) 
• 35-mm cell culture dishes (VWR, cat no. 734-2342P) 
• 100-mm cell culture dishes (VWR, cat no. 734-2341P) 
• Dissection tools: two forceps (VWR, cat no. RSGA011.130), sterile scalpel (VWR, cat no. 233-0112), 
surgical scissors (VWR, cat no. 233-1104) ! Caution These are sharp objects. 
• Warming plate (Minitüb, cat no. 12055/0200) 
• Electrical hair cutter/clipper (Oster, cat no. 76076-010) 
• Depressed microscope slide (Omnilab, cat no. 5161151) 
• Veress Pneumoperitoneum Needle (Storz, cat no. 26120JLL) ! Caution This is a sharp object. 
• 2.7-mm Hopkins telescope with 30-degree oblique view (Storz, cat no. 64018BSA) 
• Cold light fountain halogen, at least 150 W (Storz, cat no. 20131520) 
• Rubber insufflation bulb (Storz, cat no. 40924B) 
• Sharp obturator for arthroscope sheaths (Storz, cat no. 28126BS) ! Caution This is a sharp object. 
• Arthro sheet (Storz, cat no. 28126) 
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• Stereoscopic microscope with top and bottom illumination (Olympus, cat no. SZX7) 
• Inverted microinjection microscope with DIC optic (Olympus, cat no. IX-71) 
• 2× Micromanipulator (Narishige, cat no. MMO-202ND) 
• Microinjector (Eppendorf, cat no. 5247000.013) 
• CO2 incubator (Nuaire, cat no. Nu 4950E) 
• Microforge (Narishige, cat no. MF-900) 
• Capillary puller (Sutter Instrument, cat no. P-97) 
• Injection holder set (Narishige, cat no. IM-H1) 
 
REAGENT SETUP 
DEPC treatment of water. Add 1 ml DEPC to 1 L Milli-Q water to make a 0.1 % (vol/vol) solution and 
shake vigorously. Continuously stir the solution for 12 hours at room temperature (~20 °C). Autoclave 
it for 1 h to remove any trace amount of DEPC, as residual DEPC reacts with purine residues in RNA. 
 
NaCl solution for oligonucleotide annealing. Prepare a 500 mM NaCl stock solution in Milli-Q 
water, and sterilize with autoclaving or filtration. Prepare the working solution by diluting the stock 10x 
in sterile TE buffer. Keep frozen at -20 °C. 
 
Quality control of synthetic mRNA on agarose gel. Clean the running chamber, gel tray, comb and 
flask for gel preparation with 70 % (vol/vol) ethanol and decontaminate them from RNases with 
RNaseZap. Rinse the reagent off with RNase-free Milli-Q water (DEPC-treated). Incubate 1 μl of in 
vitro synthesized mRNA in 10 μl injection buffer for 1 hour at 37°C and run on an RNase-free 1 % 
(wt/vol) agarose gel. 
 
PBS + 20 % (vol/vol) FCS medium. Add 20 ml of FCS to 80 ml PBS, and sterilize the solution with a 
0.22 μm membrane filter. 
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TBE. DEPC cannot be used directly to treat Tris buffers. To prepare TBE, dilute the nuclease-free 5X 
TBE (see Reagents) in DEPC-treated water. 
 
EQUIPMENT SETUP 
Microinjection slides. The depressed microscope slides should be immersed briefly in Repel-Silane, 
air-dried for a few minutes, rinsed with water and autoclaved before each experiment. 
 
Preparation of capillaries. Injection capillary: Prepare an injection capillary with a tiphole 1-2 μm 
according to the manual of the puller. It is not possible to provide exact pulling data because each type of 
heating filament requires different conditions. Further instructions can be found at 
www.shutter.com/contact/faqs/pipette_cookbook.pdf. 
Holder capillary: Pull your holding capillary manually under a bunsen burner with a 100 μm outside 
diameter. Prepare a 30 μm hole of your holding capillary using a microforge. Alternatively, all capillaries 
can be purchased from distributors (e.g. Eppendorf). 
 
PROCEDURE 
CRITICAL At each step of the protocol use RNase-free plasticware and reagents and wear gloves 
while handling reagents and samples to prevent RNase contamination. 
Preparation of RNase-free transposon (transgene) donor plasmid TIMING 2-4 h 
1 Clone your GOI between the ITRs of a SB transposon donor plasmid (e. g., pT2/HB; see 
Reagents) by standard molecular cloning procedures. 
2 Transfer at least 5 μg transposon donor plasmid in 400 μl TE buffer into a 1.5 ml tube, and add 
400 μl phenol/chloroform/isoamyl alcohol to the tube. ! Caution This is a hazardous chemical. 
Avoid contact with skin, eyes and airways. 
3 Vortex the tube for 15 s and leave it on the bench for 2 min. Repeat this step 3 times to 
completely inactivate residual RNase. 
4 Centrifuge at 12000 × g for 5 min at room temperature. 
 15 
5 Transfer the top layer to a new, RNase-free 1.5 ml tube and add 400 μl chloroform/isoamyl 
alcohol. ! Caution This is a hazardous chemical. Avoid contact with skin, eyes and airways. 
6 Vortex for 15 s and centrifuge at 12000 × g for 5 min at room temperature. 
7 Transfer the aqueous top layer, containing the DNA, to a new RNase-free 1.5 ml tube, add 1/10 
volume of 3 M sodium acetate and 2.5 volumes of ethanol, vortex briefly, and precipitate the 
DNA for 30 min at -20 °C. 
8 Spin down at 12000 × g for 15 min at 4 °C and discard the supernatant. 
9 Wash the pellet in cold 70 % (vol/vol) ethanol (RNase-free) by keeping the ethanol on the pellet 
for 10 min on ice, centrifuge at 12000 × g for 1 min at 4 °C, and discard the supernatant. Repeat 
this step to completely remove any residual chemicals that may not be tolerated by the embryos. 
CRITICAL STEP DEPC is not tolerated by the embryos and RNase-free solutions that come in 
contact with the injected material should be purified by filtration. Therefore, use filtered, RNase-free 
water for the preparation of 70 % ethanol. 
10 Air-dry the pellet for 5-10 min and resuspend it in 100 μl EmbryoMax® injection buffer. 
11 Measure the concentration of the plasmid DNA using a NanoDrop® spectrophotometer. 
12 Make a 50 ng/μl dilution of the plasmid in EmbryoMax® injection buffer. This dilution can be 
used later for the preparation of the final injection mixture (Steps 25-26). 
Pause Point The plasmid stock and its dilution can be stored (preferably at -80 °C) until use for up to 
2 years. 
13 Thaw the plasmid DNA immediately before the preparation of the microinjection mixture (Step 
25). 
 
Preparation of the transposase mRNA TIMING 10-14h 
14 Linearize at least 2 μg of the pcGlobin2-SB100X plasmid with ClaI digestion; 1 μg of linearized 
plasmid will be necessary for one round of mRNA synthesis. Check complete linearization on a 1 
% (wt/vol) agarose gel. 
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CRITICAL STEP Supercoiled plasmid DNA runs faster, whereas open circular plasmid runs slower on 
agarose gel than the linear form. Following full digestion, bands corresponding to the open circular 
and supercoiled forms of the plasmid should be no longer visible on the gel. Consequently, linearized 
plasmid DNA produces a single band corresponding to the size of the plasmid when compared to a 
linear DNA ladder size marker. 
15 Prepare the digested plasmid RNase-free by phenol/chloroform extraction as described in steps 
2-10. In steps 2 and 5, set the volumes of the digested plasmid DNA, the 
phenol/chloroform/isoamyl alcohol and the chloroform/isoamyl alcohol to 100 μl each. This will 
decrease the liquid volume during precipitation and improve DNA recovery. 
16 Measure the concentration of the linearized plasmid DNA using a NanoDrop® 
spectrophotometer. 
17 Synthesize the mRNA using the mMessage mMachine® T7 kit following the manufacturer’s 
instructions.  
18 After mRNA synthesis, perform the Turbo DNase treatment and phenol/chloroform extraction 
suggested in the mMessage mMachine® T7 kit manual, with the modification that after the 
isopropanol precipitation following the phenol/chloroform extraction, wash the pellet twice in cold 
70 % (vol/vol) ethanol. Use filtered, RNase-free water for the preparation of 70 % ethanol. Air-
dry the pellet for 5-10 min. 
19 Resuspend the mRNA in 20 μl filtered, RNase-free water. 
Pause Point The in vitro synthesized mRNA can be stored at -80 °C for 6 months. 
20 Measure the concentration of the in vitro synthesized mRNA using a NanoDrop® 
spectrophotometer. The typical yield is around 1 μg/μl. 
21 Prepare a 1 % (wt/vol) agarose gel using nuclease-free TBE buffer, Milli-Q water treated with 
DEPC and agarose powder. ! Caution DEPC is a hazardous chemical. Avoid contact with skin, 
eyes and airways. 
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22 Load 1 μl of the in vitro synthesized mRNA (Step 19) in RNA loading buffer (supplied in the 
mMessage mMachine® T7 kit) and a double-stranded DNA size marker and run the gel. The 
SB100X mRNA prepared using the T7 promoter on the ClaI-digested pcGlobin2-SB100X runs 
on a normal agarose gel as one band between 700-800 bp in length (Fig. 2). 
? TROUBLESHOOTING 
23 Prepare 10 ng/μl dilution of the mRNA (Step 19) in EmbryoMax® injection buffer, and freeze 
down 5 μl aliquots of this dilution.  
Pause Point  The 10 ng/μl mRNA dilutions can be stored at -80 °C for 6 months. 
CRITICAL STEP It is advisable to test new batches of the EmbryoMax® injection buffer for accidental 
presence of RNase (see Reagent Setup) as the manufacturer does not guarantee that it is RNase-
free. 
 
Preparation of the microinjection mixture TIMING 1h 
24 Thaw one aliquot of the 10 ng/μl mRNA solution immediately before the preparation of the 
microinjection mixture (Step 25). 
CRITICAL STEP Avoid repeat thawing and freezing of mRNA stocks as it may cause mRNA 
degradation. 
25 Prepare 5 μl donor (transgene) plasmid (from the stock solution prepared in Step 12) in a 
concentration of 0.8 ng/μl in EmbryoMax® injection buffer. 
26 Mix the mRNA and donor plasmid solutions at a 1:1 ratio to create the final microinjection 
mixture. Prepare 2 μl aliquots of the final microinjection mixture. 
Pause Point Frozen aliquots of the microinjection mixture may be stored at -80 °C for a couple of 
months. 
 
Superovulation and insemination of zygote donors  TIMING 5 days 
27 To produce zygotes for pronuclear injection of the Sleeping Beauty transposon vectors, superovulate 
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3-8 rabbit does (3-3.5 kg body weight), either by following two different superovulation procedures 
described as Options A or B (Fig. 3), and mate or artificially inseminate them with buck semen from 
the same breed. 
A. Superovulation of donor does with pFSH/hCG: 
i. Inject follicle stimulating hormone pFSH (13.5 mg FSH/donor) subcutaneously six times, 12 
hrs apart.  
ii. Induce ovulation with an intravenous injection of 75 IU human chorionic gonadotropin (hCG) 
at 85 hours after the first pFSH injection. Fertilize the donor does by mating or by artificially 
inseminating them with fresh semen, at the time of the hCG injection.  
iii. Collect embryos 20 hours after fertilization. 
B. Superovulation of donor does with PMSG/hCG: 
i. Prime the animals with intramuscular injection of 120 IU pregnant mare serum gonadotropin 
(PMSG) per animal, 116 hours before intended embryo collection. 
ii. Inject the animals intravenously with 180 IU hCG per animal and fertilize them at 72 hours 
after the PMSG injection. 
CRITICAL STEP The timing of superovulation is critical (see Experimental Design); therefore, in case of 
using superovulation option B, it is practical to introduce both PMSG as well as hCG at 13:00 in the 
appropriate days, allowing embryo collection 20 h after the hCG injection and mating; i. e., in the morning 
on the following day. 
 
Zygote collection  TIMING 1–2 h 
CRITICAL Trained personnel with the appropriate permission are required for performing Steps 28-33. 
28 Euthanize the donor females with a mixture of 0.8 ml 2 % xylazin and 1.4 ml 10 % ketamin 
intravenously at 9:00 am (Fig. 3). 
29 Rinse the abdomen of donor animals with 70 % (vol/vol) ethanol and firmly remove the skin from 
their abdomen. 
30 Incise the peritoneum. 
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31 Collect the reproductive organs (ovaries, oviducts and the cranial parts of the uterus horns; Fig. 4A) 
and place them into PBS in a dish on a warm plate at 38.5 °C. 
CRITICAL STEP The reproductive organs are surrounded by fat tissue. Care has to be taken to avoid 
scraping or damaging the oviduct. 
32 Place your capillary (GC100-T15) into the microcapillary holder. Place 2-3 drops of PBS + 20 % 
FCS medium into a 35-mm cell culture dish, overlay the droplets with mineral oil and place the 
dish into a CO2 incubator at 38.5 °C. 
33 Collect zygotes 20 hours after hCG treatment and mating (Step 27). Insert an 18-gauge mixing 
needle connected to a 20-ml syringe from the uterus side (if this is not possible, try to wash from the 
ovary side). Flush each oviduct with pre-warmed (to 38.5 °C) PBS + 20 % FCS into 35-mm cell 
culture dishes. By counting the ovulatory follicles on the ovaries, the number of expected oocytes 
can be estimated (Fig. 4B). 
CRITICAL STEP The oviduct should be thoroughly rinsed by culture medium.  
? TROUBLESHOOTING 
34 Place 3-4 drops of PBS + 20 % FCS medium into a 100-mm cell culture dish, and separate healthy 
zygotes from debris (Fig. 4C) by washing them through the medium drops. Good quality embryos 
are free of cumulus cells and have two easily detectable pronuclei. Place the washed zygotes into 
the medium droplets overlayed with mineral oil (Step 32), and place the dish into a CO2 incubator at 
5 % CO2, 38.5 °C until microinjection, for an hour. 
CRITICAL STEP Debris should be completely removed from the medium for optimal microinjection. 
? TROUBLESHOOTING 
 
Microinjection of zygotes  TIMING 1–3 h 
35 Thaw the purified mRNA/plasmid DNA final microinjection mixture (Step 26) immediately before 
injection and keep on ice till loading your injection capillary. 
CRITICAL STEP Avoid repeated thawing and refreezing of the microinjection solution. 
36 Place a 15-20 μl drop of PBS + 20 % FCS medium in the center of a cleaned and autoclaved 
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depressed microscope slide. Cover the droplet with mineral oil. 
37 Place 20-40 zygotes into the drop and place under a stereoscopic microscope (Fig. 4D). 
CRITICAL STEP Do not handle too many zygotes at once. 
38 Place the depressed slide onto the heated stage of the microinjection microscope. 
39 Adjust the air-driven holding capillary to an angle of 35-40°, and carefully dip into the medium droplet 
in the depressed microscope slide. Fill the capillary with a minimal amount of medium and catch the 
first embryo by a slight negative pressure. 
40 Fill the injection capillary (GC100-TF15) by placing the base of the capillary into the Eppendorf tube 
containing the microinjection mixture kept on ice. Wait 10 seconds till the mixture reaches the tip of 
the capillary. Insert the injection capillary into the connector piece and dip it into the medium droplet. 
Position it to the zygote. 
CRITICAL STEP Prevent breakage of your capillaries. Remove all air bubbles from the injection capillary. 
41 Position your zygote - the best position is when the female and the male pronuclei are aligned in a 
row equatorially. Focus your microscope to the male pronucleus (usually the larger one) and adjust 
your injection capillary to see the tip of it sharply when it is in a 12 o’clock position. Keep your 
injection capillary parallel to the pronucleus (Fig. 4E). Penetrate the zygote and the pronucleus, and 
inject carefully by pushing your syringe or automatic microinjector. Withdraw the capillary when the 
male pronucleus is swelling (Fig. 4F). Microinject all viable zygotes one by one. 
CRITICAL STEP Be sure that you penetrate the pronucleus because it is very flexible. The clearly visible 
swelling of the pronucleus is an indication of injecting ~2-3 pl mRNA/plasmid solution. The female 
pronucleus can also be injected. In some cases the female pronucleus is more visible in rabbits (rabbit 
zygotes can be darker than rodents’); however, it is smaller and more difficult to inject. 
CRITICAL STEP If your injection capillary becomes clogged, replace it with a new one. 
CRITICAL STEP Carefully separate injected and uninjected zygotes to prevent mixing. 
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Reimplantation of injected zygotes  TIMING 15–30 min/recipient 
CRITICAL Trained personnel with the appropriate permission are required for performing these steps. 
42 To prepare recipient does, apply a single intramuscular injection of 0.25 ml GnRH 24 hours before 
embryo transfer (Fig. 3). Remove forage from recipient does 12-14 hours before embryo transfer. 
43 Culture the microinjected embryos for one hour in 5 % CO2 at 38.5°C before reimplantation and 
select the embryos most suitable for embryo transfer (Fig. 4G). 
? TROUBLESHOOTING 
44 Anesthesize recipient females with a mixture of 5 mg/kg body weight 2 % xylazin and 44 mg/kg body 
weight 10 % ketamin intravenously. Anesthesia lasts 30-45 min. 
CRITICAL STEP Introduce the ketamine and xylazin solution stepwise and slowly. Fast administration 
might cause bradycardia. 
45 Remove the rest of the urine with gentle massage of the lower part of the donor’s body. Shave the 
abdominal region of the anesthetized recipient doe, and clean with a surgical soap solution such as 
betadine. Place and fix the recipient doe in a hanging position. Introduce the endoscopic trocar 
(Veress Pneumoperitoneum Needle) through a small (1 cm) incision just above the umbilical point as 
shown in Fig. 4H. 
46 Inflate the abdomen with air using the rubber insufflation bulb. Remove the Veress trocar and insert 
the arthro sheet with sharp obtulator. Replace the obtulator with Hopkins telescope. Reinflate the 
abdomen. 
CRITICAL STEP Avoid injury of inner organs. 
47 Examine the ovaries of the recipients for signs of induced ovulation (such as those shown in Fig. 
4A). Do not transfer embryos into recipients that did not react to hormone treatment. 
48 Insert the cannula with its needle, and find the ampulla of the oviduct. Exchange the needle with the 
transfer capillary filled with the embryos through the cannula, and inject it gently with 10 μl of culture 
medium (Fig. 4I). Remove the cannula with the empty capillary and the endoscope. Evacuate the air 
and close the abdomen with a suture wound clip. Transfer 8-12 embryos into each oviduct of a 
recipient doe. Endoscopic embryo transfer is minimally invasive42. 
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49 Post-operative care: administer 1ml broad-spectrum antibiotics (Shotapen INJ) intraperitoneally. 
Place the recipient rabbit carefully into the home cage in the rabbit facility and resupply forage when 
animals fully have recovered from the anesthesia. F0 animals are born after a 30-32 days-long 
pregnancy of recipient does. 
CRITICAL STEP A specific feature of the rabbit embryo is a mucin layer, which is formed around the 
embryo in the oviduct. The thickness of the mucin layer is an important factor for successful implantation of 
rabbit embryos43. Therefore, it is important to transfer the embryos as soon as possible following a short in 
vitro culturing, at the end of which 20-80% of the injected rabbit embryos should be in two-cell stage before 
reimplantation. Keep in mind that due to the rapid cell divisions during early embryogenesis, mosaicism is 
more probable in rabbits than in rodents. 
? TROUBLESHOOTING 
 
Genotyping of transgenic animals - confirming transposon insertions by PCR  TIMING 2.5 hours 
50 Isolate genomic DNA from ear biopsies of F0 animals. A simple and reliable protocol for DNA 
isolation from tissue samples is available in Laird et al. (1991)44. 
51 Set up a PCR reaction in a 25 μl volume containing the components below:  
Component  Amount per reaction Final  
PCR buffer (10x) 
MgCl2 (25 mM) 
dNTP (10 mM) 
Primer SB short (10 pmol/μl) (Table 1) 
Primer Tbal rev (10 pmol/μl) (Table 1) 
Genomic DNA 
Taq DNA polymerase 
H2O 
2.5 μl 
1.5 μl 
0.5 μl 
0.8 μl 
0.8 μl 
1 μl 
0.4 μl 
17.5 μl 
1x 
1.5 mM 
0.2 mM 
8 pmol 
8 pmol 
~200 ng 
2 U 
- 
 
CRITICAL STEP Include donor plasmid DNA in a separate reaction as a positive control for the PCR. 
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52 Run the PCR reaction using the following conditions: 
 
 
 
 
 
 
 
53  Run a 5 μl aliquot of the PCR product on a 1 % (wt/vol) agarose gel. A PCR product of 201 bp 
in length indicates the presence of genomically integrated SB transposons. An example result of 
genotyping F1 rabbit offspring is shown in Fig. 5A. 
? TROUBLESHOOTING 
 
Identification of individual transgene integrations by ligation-mediated PCR (LMPCR)  TIMING 
1-2 weeks 
54 Digest 1 μg genomic DNA of F0 animals with BfaI, and in a separate reaction 1 μg with DpnII 
(Fig. 5B), in 50 μl final volumes. Include a negative control sample (genomic DNA isolated from 
a non-transgenic animal) as well. Follow the instructions of the enzyme supplier. To reach 
complete digestion, incubate the reaction for 3 hours at 37 oC. 
CRITICAL STEP Always use high quality genomic DNA as template for PCR. Good quality genomic 
DNA runs on an agarose gel as a dominant, high molecular weight band (Fig. 5C). 
55 Add 50 μl phenol/chloroform/isoamyl alcohol to each tube. ! Caution This is a hazardous 
chemical. Avoid contact with skin, eyes and airways.  
56 Vortex for 10 s and leave on the bench for 2 min. Repeat this step 3 times. 
57 Centrifuge the samples at 12000 × g for 5 min at room temperature. 
58 Transfer the top layer (~50 μl) to a new 1.5-ml tube, add 5 μl (1/10 volume) of sodium acetate 
and 125 μl (2.5 volumes) of ethanol, shake well and let the digested DNA precipitate for 30 min 
at -20 °C. 
Cycle number Denature Anneal Extend Hold 
1 
2–31 
32 
33 
94 °C, 5 min 
94 °C, 1 min 
  
55 °C, 30 s 
  
72 °C, 30 s 
72 °C, 7 min 
  
 
 
4 °C 
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59 Spin down at 12000 × g for 15 min at 4 °C, and discard the supernatant. 
CRITICAL STEP The pellet is barely visible. To avoid loss of DNA, remove the liquid using a 200 μl 
pipette tip by touching only the wall of the tube that faced the inner side of the rotor. 
61 Wash the pellet in cold 70 % (vol/vol) ethanol. Keep the ethanol on the pellet for 10 min. 
61 Spin down at 12000 × g for 15 min at 4 °C, and discard the supernatant. 
CRITICAL STEP The pellet is barely visible. To avoid loss of DNA, remove the liquid using a 200 μl 
pipette tip by touching only the wall of the tube that faced the inner side of the rotor. 
62 Air-dry the pellet for 5-10 min, and resuspend it in 20 μl sterile Milli-Q water. 
63 Measure the concentration of the digested DNA using a NanoDrop® spectrophotometer. The 
typical yield is between 30-50 ng/μl. 
64 To check digestion run 200 ng of each sample on a 1 % (wt/vol) agarose gel. The digested DNA 
should run as a smear centered between 0.5-1 kb in size (Fig. 5D). 
Pause Point The digested genomic DNA samples can be stored at 20 °C for up to 1 year. 
65 Prepare the double-stranded linkers by mixing the Linker(+) oligo with the Linker(-)BfaI or with 
the Linker(-)DpnII oligo (Table 1) in separate tubes at a final concentration of 10 pmol/μl of each 
oligo in 100 μl TE buffer containing 50 mM NaCl.  
66 Place the tubes containing the oligonucleotide solutions into a boiling water bath for 2 min, 
switch off the heating, and leave the tubes in the bath overnight to allow a slow cool down and 
hybridization of the two single-stranded oligonucleotides to form the double-stranded linker. 
Pause Point The annealed double-stranded oligonucleotides can be stored at -20 °C for up to 1 year. 
67 Ligate the BfaI linkers and the DpnII linkers to the corresponding BfaI- and DpnII-digested 
genomic DNA samples, respectively (Fig. 5B). Set up the ligation reaction containing the 
components below, and incubate overnight at 16 °C. 
Component  Amount per reaction Final  
Ligase buffer (10x) 
BfaI- or DpnII-digested genomic DNA  
Annealed BfaI or DpnII linker (10 pmol/μl) 
T4 DNA Ligase  
H2O 
5 μl 
X μl 
2 μl 
3 μl 
X μl 
1x 
150 ng 
20 pmol 
18 U 
to final volume of 50 μl  
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68 Set up the 1st PCR in a 50 μl reaction volume containing the components below: 
  
Component  Amount per reaction Final  
PCR buffer (10x) 
MgCl2 (25 mM) 
dNTP (10 mM) 
Linker Primer (10 pmol/μl) (Table 1) 
Tbal rev3s primer (10 pmol/μl) (Table 1) 
Ligated DNA (Step 67) 
Taq DNA polymerase 
H2O 
5 μl 
3 μl 
1 μl 
1 μl 
1 μl 
2 μl 
0.5 μl 
36.5 μl 
1x 
1.5 mM 
0.2 mM 
10 pmol 
10 pmol 
- 
2.5 U 
- 
     
69 Run the 1st PCR reaction using the following conditions: 
 
 
 
 
 
 
 
 
 
 
 
 
70 Set up the 2nd PCR in a 50 μl reaction volume containing the components below: 
 
Component  Amount per reaction Final  
PCR buffer (10x) 
MgCl2 (25 mM) 
dNTP (10 mM) 
Nested Primer (10 pmol/μl) (Table 1) 
Tbal (10 pmol/μl) (Table 1) 
100x diluted 1st PCR sample 
Taq DNA polymerase 
H2O 
5 μl 
3 μl 
1 μl 
1 μl 
1 μl 
1 μl 
0.5 μl 
37.5 μl 
1x 
1.5 mM 
0.2 mM 
10 pmol 
10 pmol 
- 
2.5 U 
- 
 
71 Run the 2nd PCR reaction using the following conditions: 
 
 
 
 
 
 
 
Cycle number Denature Anneal Extend Hold 
1 
2–11 
12-36 
37 
38 
96 °C, 2 min 
92 °C, 40 s 
92 °C, 40 s 
  
60 °C -1 oC/cycle, 40 s 
50 °C, 40 s 
  
72 °C, 2 min 
72 °C, 1 min 
72 °C, 10 min 
  
 
 
 
4 °C 
Cycle number Denature Anneal Extend Hold 
1 
2–7 
8-21 
22 
23 
96 °C, 2 min 
92 °C, 40 s 
92 °C, 40 s 
  
66 °C -1 oC/cycle, 40 s 
59 °C, 40 s 
  
72 °C, 1 min 
72 °C, 1 min 
72 °C, 10 min 
  
 
 
 
4 °C 
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72 Run a 10-μl aliquot of the PCR product on a 1 % (wt/vol) agarose gel. An example result is 
shown in Fig. 5E. Each band represents a unique transposon (transgene) genomic integration. 
73 If strong, distinct bands are visible, isolate them from the gel using the QIAquick Gel Extraction 
Kit according to the manufacturer’s instructions, and sequence them. Multiple bands often 
represent multiple integrations, and lower intensity bands may represent mosaic integrations - all 
of which need to be isolated from the gel, subcloned and sequenced. One should be able to 
identify the TA target dinucleotides immediately flanking the ITR in the genomic sequence, the 
BfaI and/or DpnII recognition sites and the linkers that had been ligated to the DNA ends. The 
PCR amplifications applied in parallel on the BfaI- and DpnII-digested DNA methods help the 
user to recover all integrations.  
74 Map the insertion sites by a BLAT or BLAST search of the DNA sequence directly flanking the 
transposon, at the UCSC Genome Bioinformatics website (http://genome.ucsc.edu/cgi-
bin/hgBlat) or at the NCBI website (http://blast.ncbi.nlm.nih.gov/Blast.cgi).  
 
Tracking individual transgene integration sites by locus-specific PCR  TIMING 1 week  
75 Design PCR primers matching the integration loci mapped in the founder animals (Step 74). 
Avoid designing primers that would bind to repetitive elements and thus amplify non-specific 
PCR products. The BLAT search at the UCSC Genome Bioinformatics website directly provides 
a RepeatMasker annotation of the genomic loci where the SB transposons have integrated. 
When using BLAST at the NCBI website select “map viewer” for a given BLAST hit, then select 
“maps & options” and choose “repeats” to see the RepeatMasker annotation. After the 
identification of genomic regions free of repetitive sequences in the neighborhood of the SB ITR, 
design at least one locus-specific primer with a Tm between 55-60oC and a length between 20-25 
nt. Run a BLAT or BLAST search with the new primer sequences to make sure that they do not 
bind to other genomic locations. In addition, general rules for PCR primer design can be found 
for example at http://www.premierbiosoft.com/tech_notes/PCR_Primer_Design.html. 
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76 Perform the locus-specific PCR with the primer designed in Step 75 and primer Tbal (Table 1) to 
trace specific transgene integrations by the presence or absence of an amplified product. To 
maximize specificity of primer annealing to the genomic target, the use of touchdown PCR is 
recommended consisting of 5-10 touchdown cycles stepwise decreasing the annealing 
temperature by 1 oC per cycle down to the final annealing temperature, at about 2 °C below the 
Tm of the lower Tm primer, followed 25 additional standard cycles. Supplementary Fig. 1 shows 
an example of locus-specific PCR test of a rat founder and its F1 descendants.  
 
[CE: Table 1 is in the bottom of the manuscript.] 
 
 
? TROUBLESHOOTING 
Troubleshooting advice can be found in Table 2. 
 
 
TIMING  
Steps 1-13, preparation of transposon (transgene) donor plasmid: 2-4 h 
Steps 14-23, preparation of the transposase mRNA: 10-14 h 
Steps 24-26, preparation of the microinjection mixture: 1 h 
Step 27, superovulation and insemination of zygote donors: 5 days 
Steps 28-34, zygote collection: 1–2 h  
Steps 35-41, microinjection of zygotes: 1–3 h 
Steps 42-49, reimplantation of injected zygotes: 15–30 min/recipient  
Steps 50-53, genotyping of transgenic animals - confirming transposon insertions by PCR: 2.5 hours 
Steps 54-74, identification of individual transgene integration events by LMPCR: 1-2 weeks  
Steps 75-76, tracking individual transgene integration sites by locus-specific PCR: 1 week 
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Table 2| Troubleshooting table. 
Step Problem Possible reason Possible solution 
Step 22 Smear is 
detected in the 
size range 
lower than 800 
bp. 
 
More than two 
bands are 
detected. 
RNase contamination 
occurred during or after in 
vitro mRNA synthesis. 
 
 
 
Different length products of 
the in vitro mRNA synthesis. 
 
The mRNA runs aberrantly 
due to the formations of 
secondary structures  
Change solutions and maintain RNase-free 
conditions. 
 
 
 
 
Consult the troubleshooting instructions of the 
mMessage mMachine® T7 kit.  
Step 33 Number of 
collected 
embryos is less 
than 20 per 
donor doe  
Suboptimal donor animals. Do not use overweight or over-aged donor 
rabbits.  
 
The reproductive performance of rabbits is 
seasonal, so some periods of the year (middle of 
summer) are suboptimal for superovulation. 
Step 34 Unfertilized 
oocytes within a 
cumulus cloud.  
 
 
 
 
Poor embryo 
quality. 
 
Bad quality semen. 
 
 
Artifical insemination was 
ineffective.  
 
 
Embryos were overheated or 
overexposed to light.  
 
Check the quality of the semen (motility of the 
fresh semen should be over 70 %).  
 
Check the insemination catheter. Insemination is 
successful only when the semen remains 
completely inside the reproductive tract.  
 
Be sure that culture medium droplets are always 
covered by mineral oil. Do not expose the 
zygotes to excessive light. 
Step 43  Decreased 
viability of the 
injected 
embryos (as of 
lysed cell after 
microinjection 
Fig 4G)  
Residual harmful chemicals 
in the microinjection mixture.  
 
 
 
 
 
 
 
 
Toxicity due to excess 
amounts of DNA in the 
microinjection mixture. 
 
Suboptimal culture 
conditions. 
 
 
 
 
Rough physical handling of 
the zygotes.  
 
Carefully washing the precipitated plasmid DNA 
and mRNA with 70 % ethanol (Steps 9 and 18) is 
important for the removal of residual 
phenol/chloroform.  
 
DEPC is not tolerated by the ova. Consequently, 
RNase-free solutions that come in contact with 
the injected material should be purified by 
filtration.  
 
Adjust the concentration of your construct 
exactly.  
 
 
Check the quality of the culture medium (pH, test 
FCS before use). 
 
Check the CO2 incubator. Rabbit zygotes prefer 5 
% CO2, 38.5 °C.  
 
Try to avoid applying strong negative pressure 
while holding the zygotes. Inject the pronucleus 
carefully. 
Step 49  Pups are not 
born.  
 
 
Suboptimal reimplantation 
procedure. 
 
 
Swelling of the oviduct during embryo transfer 
should be visible.  
 
Be sure not to damage the oviduct with the 
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Litter size too 
small or too 
large.  
 
 
 
 
 
 
 
Suboptimal embryo transfer. 
 
 
 
 
 
 
 
 
 
transferring  needle.  
 
Cultivate the injected embryos for at least 72 
hours in parallel with the embryo transfer - most 
of the embryos should reach the early blastocyst 
stage. Use special cultivation media45. 
 
Too small litter sizes might cause skeletal 
abnormalities of the overfed newborns. Too large 
litter sizes (≥ 10) might result in suboptimal 
weight gain of the pups. Therefore the 
equalization of litter sizes, or cross-feeding the 
newborns with any other lactating doe which is 
approximately in the same period of lactation is 
an option. Please note that the age of the cross-
fed pups should be synchronized with the original 
litter. 
 
For more detailed advice from transgenic 
experts, subscribe to transgenic-list at 
http://www.transtechsociety.org/transgeniclist.php 
Step 53 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No or few 
transgenic 
newborns 
delivered 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Integrity of transposase 
mRNA compromised. 
 
 
 
 
 
 
 
Larger transgenes may 
cause a drop of transgenesis 
rates. 
 
 
 
 
Apparent low transgenic 
rates may be due to 
transgene detection 
problems, e. g.,  because the 
genomic DNA template used 
in the PCR tests is 
degraded. 
Always use RNase-free laboratory plastic and 
glassware and wear gloves while handling 
reagents and samples to prevent RNase 
contamination. 
 
Do not re-use the same aliquot of the injection 
mixture after microinjection (Step 26) due to the 
increased risk of RNase contamination.  
 
Increasing the amount of transposon (transgene) 
donor plasmid in the final injection mixture 
(preferably not over 2 ng/μl; Step 26) may help to 
increase the efficiency in case of larger 
transgenes.  
 
 
Always use high-quality genomic DNA for PCR.  
 
 
 
 
 
ANTICIPATE RESULTS 
The pregnancy rate of foster mothers is between 40-60 %, the ratio of pups born compared to the 
number of transferred microinjected embryos is around 10 %. The efficiency of Sleeping Beauty 
transgenesis in rabbits (transgenic founders in relation to all animals born alive) should be 15 % or 
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higher. We found germline transmission from F0 to F1 to be 100 % with transgene segregation close 
to Mendelian rates (44%)30. Germline transmission from F1 to F2 corresponded to the Mendelian rates 
for all rabbit lines with single-copy integration, which were confirmed by LMPCR (Fig. 5E). Transgene 
silencing was not experienced through three generations. 
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FIGURE LEGENDS 
 
 
Figure 1. Application of Sleeping Beauty transposons for gene delivery. (A) A bi-component 
transposon system for delivering transgenes in plasmids. One component contains a gene of interest 
(GOI) cloned between the transposon inverted terminal repeats (ITR, black arrows) encoded by a 
plasmid. The other component is either a transposase expression plasmid, or synthetic mRNA 
encoding the transposase. (B) The transposon carrying a GOI is excised from the donor plasmid and 
is integrated at a chromosomal site by the transposase (purple spheres). 
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Figure 2. In vitro mRNA synthesis. mRNA quality can be determined by standard agarose 
electrophoresis and ethidium bromide staining. Samples run on 1 % RNase-free non-denaturing 
agarose gel. Lanes: M, DNA size marker; 1, 1 μl in vitro synthesized SB100X mRNA. 
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Figure 3. Timelines for rabbit manipulations. Timing (in days) of the important protocol steps for 
donor hormonal treatment (A) and (B), ending with parturition and genotyping of the F0-offspring. 
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Figure 4. Overview of rabbit transgenesis. (A) Excision of reproductive organs from donors. (B) 
Embryo flushing. (C) and (D) Embryo collection in rabbits. Good quality embryos are free of cumulus 
cells and have two easily detectable pronuclei. (E) A rabbit zygote before microinjection. (F) Zygote 
with swelling pronucleus. (G) Different zygotes clockwise: zygote with reduced visibility of pronuclei, 
two-cell-stage embryo, lysed cell after microinjection, an ideal zygote for embryo transfer. (H) 
Positioning of the cannula and the obtulator with Hopkins telescope during endoscopic transfer. (I) 
Simulated embryo transfer. Note the quality of the ovary and the cannula in the oviduct. 
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Figure 5.  Identification of transgene integration by PCR. (A) Identification of integrated transposon 
sequences from rabbit genomic DNA samples by PCR with primers that amplify the left ITR of SB. (B) 
Outline of the LMPCR procedure. Digestion of genomic DNA with the frequently cutting restriction 
enzymes BfaI and DpnII and ligation of linkers with a known sequence allows for specific LMPCR 
amplification of transposon/genomic DNA junctions using primers specific to the transposon ITR (blue 
arrows) and the linkers (green arrows). Linker-to-linker amplifications are blocked by the 3’-amino 
modifications of the Linker(-) oligo40 (Table 1). Amplification products are sequenced for comparison to the 
reference genome. GOI, gene of interest; ITR, inverted terminal repeat. (C) Agarose gel with 500 ng 
genomic DNA samples prepared from rabbit founders. M, DNA size marker. (D) Agarose gel with 200 ng 
BfaI-digested genomic DNA samples of rabbit founders. M, DNA size marker. (E) Agarose gel with LMPCR 
products. M, DNA size marker.  
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Supplementary Figure 1: Locus-specific PCR test of a rat founder and its F1 descendants. The founder 
of these F1 animals carried three SB integrations (in chr2, chr4 and chr16), which were transmitted to 
13 descendants in different combinations. M, DNA size marker. 
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Table 1. Primer sequences  
 
Oligo 
designation Sequence Description and use 
SB short  
 
 
5’-TACAGTTGAAGTCGGAAGTTTACATAC-3’ 
 
 
Transposon-specific 
primer used in PCR with 
Tbal rev. Step 51 
Tbal rev 
 
 
5’-GAATTGTGATACAGTGAATTATAAGTG-3’ 
 
Transposon-specific 
primer used in PCR with 
SB short. Step 51 
Linker(+) 5’-GTAATACGACTCACTATAGGGCTCCG 
CTTAAGGGAC-3’ 
Annealed either with 
Linker(-) BfaI or Linker(-) 
DpnII to form double 
stranded linker for LM-
PCR. Step 65 
Linker(-)BfaI 5’-p-TAGTCCCTTAAGCGGAG-Amino-3’ 
 
Annealed with Linker(+). 
The 3’ C7 amino 
modification prevents 
polymerase extension. 
Step 65 
Linker(-)DpnII 5’-p-GATCGTCCCTTAAGCGGAG-Amino-3’ 
 
Annealed with Linker(+). 
The 3’ C7 amino 
modification prevents 
polymerase extension. 
Step 65 
Linker Primer 5’-GTAATACGACTCACTATAGGGC-3’   
 
Linker-specific primer 
used in the first round of 
PCR with Tbal rev3s 
(transposon specific). 
Step 68 
Tbal rev3s 5’-CATGACATCATTTTCTGGAATT-3’  Transposon-specific 
primer used in the first 
round of PCR with 
Linker Primer (linker 
specific). Step 68 
Nested Primer 5’-AGGGCTCCGCTTAAGGGAC-3’   Linker-specific primer 
used in the second 
round of PCR with Tbal 
(transposon specific). 
Step 70 
Tbal 5’-CTTGTGTCATGCACAAAGTAGATGTCC-3’  Transposon-specific 
primer used in the 
second round of PCR 
with Nested Primer 
(linker specific). Step 70 
